← All companies

Moderna

3 reports

Research on this company

Goldman Sachs

Goldman Sachs: Moderna’s cancer vaccine meets Phase III endpoint: why does Goldman Sachs favor expansion into kidney cancer while maintaining a Neutral rating?

Intismeran combined with Keytruda significantly improved recurrence-free survival after melanoma surgery, while early pancreatic cancer data provide mechanistic support for expansion into kidney cancer. But the wait for treatment to take effect, tissue sample requirements for manufacturing, and immature overall survival data still constrain the realization of the platform’s value.